<DOC>
	<DOCNO>NCT00905047</DOCNO>
	<brief_summary>The scope trial determine preference patient , randomization cross-over , one two treatment . Another objective trial ass compare safety treatment .</brief_summary>
	<brief_title>Xeloda UFT ( Tegafur-uracil ) With Folinic Acid Advanced Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Further study detail provide Centre Oscar Lambret .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Locally advanced metastatic colorectal cancer Age &gt; = 18 year old PSWHO &lt; = 2 Polynuclear neutrophil leukocyte &gt; = 1500/mm3 , platelet &gt; = 100000/mm3 Total bilirubin &lt; = 3 ULN , ASATALAT &lt; = 2.5 ULN Effective contraception Written inform consent sign Concomitant radiotherapy Contraindication fluoropyrimidines Treatment sorivudine chemical analog brivudine Severe hepatic insufficiency Severe renal insufficiency Pregnant lactate woman Hypersensitivity capecitabine , 5FU , tegafur one excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>colo-rectal cancer</keyword>
	<keyword>advanced</keyword>
	<keyword>metastatic</keyword>
	<keyword>locally advanced metastatic colo-rectal cancer</keyword>
</DOC>